WORLD PEPTIDEFOUNDATION

Where is Lanreotide being studied?

Find registered human studies, phases, products, recruitment status and reported research locations around the world. Registry search matches are separate from this profile’s reviewed evidence.

Find studies for Lanreotide →Worldwide registry directory

Scientific intelligence record

Experience 2.0

Somatostatin analog

Lanreotide

Lanreotide is a synthetic cyclic octapeptide somatostatin analog with high affinity particularly for somatostatin receptor subtypes 2 and 5. Receptor activation suppresses growth-hormone secretion and multiple gastroenteropancreatic hormones and can exert antiproliferative effects in selected somatostatin-receptor-expressing neuroendocrine tumors. Depot and Autogel formulations provide prolonged exposure; approved indications and administration requirements vary by product and jurisdiction.

Record status

Traceability partial

Last meaningful update: 9/20/2026

Evidence searched through:
Not recorded
Assessment updated:
9/20/2026
Documented human review:
No documented human review recorded
Automated scientific assessment:
None recorded
AI source check:
9/26/2026

Published source links and profile text pass separate gates. Only a documented human review is labelled as human review; an automated scientific assessment applies deterministic checks, and an AI source check confirms only that a source exists and matches its identifiers. A source count alone does not establish a review.

Evidence coverage has three distinct layers. The corpus count is a transparent screening inventory, the featured set contains study-level tiering and interpretation, and the published-source count contains records promoted through the institutional publication workflow. Source validation, editorial publication, and scientific appraisal are separate decisions; these numbers must not be merged.

Ranked research corpus

500

Categorized publications with provisional ranking; scientific review remains separate.

Featured tiered studies

0

Cornerstone publications with study-level interpretation, limitations, and tier disclosure.

Research domains

6

Clinical and scientific questions synthesized independently across the evidence atlas.

Published source records

25

Database records promoted through the governed publication workflow—not the corpus total.

Corpus generated 2026-09-18. Counts remain separately labeled so screening is not represented as completed review.

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observationArchive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Ranked research corpus

500

Categorized screening records; proposed rankings remain pending human appraisal.

Featured tiered studies

0

Cornerstone studies with published study-level interpretation and tier disclosure.

Research domains

6

Independent evidence dossiers covering the major research questions.

Published source records

25

Source records published through the governed workflow; this count does not certify scientific conclusions.

Contradictions

0

Conflicting evidence relationships that remain visible.

Research gaps

1

Questions the current record identifies as unresolved.

Connected media

0

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

6 published domain syntheses connected to 0 featured studies

Lanreotide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded synthesis, confidence level, evidence context, limitations, geographic applicability, regulatory interpretation, and research gaps. Publication of these syntheses is separate from the scientific review status shown above.

Inspect the reconciled evidence atlas
Inspect the published evidence record25 governed records · titles, provenance, and original-source linksOpen records ↓
2014Phase 3 human evidence

Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects are limited.

Authors
Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, Alexandria T Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley
Source
The New England journal of medicine
DOI
10.1056/nejmoa1316158
PubMed
25014687
Open original source
2014Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.

Methodological shortcomings often compromise investigations into the effects of primary somatostatin-analog treatment on tumor size in acromegaly.

Authors
Philippe J Caron, John S Bevan, Stephan Petersenn, Daniel Flanagan, Antoine Tabarin, Gaëtan Prévost, Pascal Maisonobe, Antoine Clermont, PRIMARYS Investigators
Source
The Journal of clinical endocrinology and metabolism
DOI
10.1210/jc.2013-3318
PubMed
24423301
Open original source
2016Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.

To evaluate the effects of lanreotide Autogel on patient-reported outcomes and association with biochemical control, using PRIMARYS data.

Authors
Philippe J Caron, John S Bevan, Stephan Petersenn, Aude Houchard, Caroline Sert, Susan M Webb, PRIMARYS Investigators Group
Source
Pituitary
DOI
10.1007/s11102-015-0693-y
PubMed
26603536
Open original source
2005Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel.

Somatostatin analogs are the first-line medical therapy for acromegaly, and the treatment of this disease has been simplified by the development of extended-release formulations of these analogs.

Authors
Joseph M Cendros, Concepción Peraire, Iñaki Fernández Trocóniz, Rossend Obach
Source
Metabolism: clinical and experimental
DOI
10.1016/j.metabol.2005.04.014
PubMed
16154424
Open original source
2019Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.

Urinary 5-hydroxyindoleacetic acid (5-HIAA) is an established biomarker in neuroendocrine tumors and carcinoid syndrome; however, its role in nonfunctional neuroendocrine tumors is not defined.

Authors
Marianne E Pavel, Alexandria T Phan, Edward M Wolin, Beloo Mirakhur, Nilani Liyanage, Susan Pitman Lowenthal, George A Fisher, Aaron I Vinik, CLARINET Study Investigators
Source
The oncologist
DOI
10.1634/theoncologist.2018-0217
PubMed
30355775
Open original source
2016Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.

To evaluate the efficacy and safety of lanreotide depot/autogel 120 mg for the control of carcinoid syndrome (CS) symptoms in patients with neuroendocrine tumors (NETs).

Authors
Aaron I Vinik, Edward M Wolin, Nilani Liyanage, Edda Gomez-Panzani, George A Fisher, ELECT Study Group *
Source
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
DOI
10.4158/ep151172.or
PubMed
27214300
Open original source
2018Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.

This ELECT prospective analysis examined lanreotide depot/autogel for carcinoid syndrome (CS) symptom control in patients with neuroendocrine tumors (NETs) who were responsive to prior octreotide (prior octreotide group) compared with patients who were naïve to prior somatostatin analogue treatment (de novo group).

Authors
George A Fisher, Edward M Wolin, Nilani Liyanage, Susan Pitman Lowenthal, Beloo Mirakhur, Rodney F Pommier, Montaser Shaheen, Aaron I Vinik, ELECT Study Investigators
Source
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
DOI
10.4158/ep172000.or
PubMed
29547049
Open original source
2014Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.

Many patients with acromegaly do not achieve biochemical control despite receiving high doses of the first-generation somatostatin analogues octreotide or lanreotide.

Authors
Mônica R Gadelha, Marcello D Bronstein, Thierry Brue, Mihail Coculescu, Maria Fleseriu, Mirtha Guitelman, Vyacheslav Pronin, Gérald Raverot, Ilan Shimon, Kayo Kodama Lievre, Juergen Fleck, Mounir Aout
Source
The lancet. Diabetes & endocrinology
DOI
10.1016/s2213-8587(14)70169-x
PubMed
25260838
Open original source
2013Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.

The somatostatin analog lanreotide Autogel has proven to be efficacious for treating acromegaly in international studies and in clinical practices around the world.

Authors
Akira Shimatsu, Akira Teramoto, Naomi Hizuka, Kazuo Kitai, Joaquim Ramis, Kazuo Chihara
Source
Endocrine journal
DOI
10.1507/endocrj.ej12-0417
PubMed
23337477
Open original source
2020Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).

Lanreotide autogel is a somatostatin analog (SSA) approved for the treatment of acromegaly in 73 countries worldwide; however, it is not yet approved in China.

Authors
Zhenmei An, Ting Lei, Lian Duan, Pei Hu, Zhongping Gou, Lihui Zhang, Lucie Durand-Gasselin, Nan Wang, Yan Wang, Feng Gu, LANTERN study investigators
Source
BMC endocrine disorders
DOI
10.1186/s12902-020-0524-7
PubMed
32366244
Open original source
2006Phase 3 human evidence
Evidence strength A · 91/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.

Depot somatostatin analogues are well accepted as either adjuvant or primary therapy for acromegaly, and their long dosage intervals facilitate adherence to treatment.

Authors
T Lucas, R Astorga, Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly
Source
Clinical endocrinology
DOI
10.1111/j.1365-2265.2006.02595.x
PubMed
16918950
Open original source
2000Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.

The most effective option for the medical treatment of patients with acromegaly is the use of somatostatin analogues.

Authors
P Chanson, V Boerlin, C Ajzenberg, Y Bachelot, P Benito, J Bringer, P Caron, B Charbonnel, C Cortet, B Delemer, F Escobar-Jiménez, L Foubert
Source
Clinical endocrinology
DOI
10.1046/j.1365-2265.2000.01134.x
PubMed
11106918
Open original source
2009Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months.

Lanreotide is a somatostatin analogue used for the treatment of acromegaly and neuroendocrine tumours.

Authors
Iñaki F Trocóniz, Josep-María Cendrós, Concepción Peraire, Joaquim Ramis, Maria J Garrido, Paolo F Boscani, Rosendo Obach
Source
Clinical pharmacokinetics
DOI
10.2165/0003088-200948010-00004
PubMed
19071884
Open original source
2018Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.

Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive cyst formation in both kidneys and loss of renal function, eventually leading to a need for kidney replacement therapy.

Authors
Esther Meijer, Folkert W Visser, Rene M M van Aerts, Charles J Blijdorp, Niek F Casteleijn, Hedwig M A D'Agnolo, Shosha E I Dekker, Joost P H Drenth, Johan W de Fijter, Maatje D A van Gastel, Tom J Gevers, Marten A Lantinga
Source
JAMA
DOI
10.1001/jama.2018.15870
PubMed
30422235
Open original source
2016Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.

In the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged progression-free survival (PFS) in patients with metastatic pancreatic/intestinal neuroendocrine tumours (NETs).

Authors
Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, Alexandria T Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley
Source
Endocrine-related cancer
DOI
10.1530/erc-15-0490
PubMed
26743120
Open original source
2019Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.

Polycystic liver disease is the most common extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD).

Authors
Rene M M van Aerts, Wietske Kievit, Hedwig M A D'Agnolo, Charles J Blijdorp, Niek F Casteleijn, Shosha E I Dekker, Johan W de Fijter, Maatje van Gastel, Tom J Gevers, Liyanne F M van de Laarschot, Marten A Lantinga, Monique Losekoot
Source
Gastroenterology
DOI
10.1053/j.gastro.2019.04.018
PubMed
31022403
Open original source
2009Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

Therapy for polycystic liver is invasive, expensive, and has disappointing long-term results.

Authors
Loes van Keimpema, Frederik Nevens, Ragna Vanslembrouck, Martijn G H van Oijen, Aswin L Hoffmann, Helena M Dekker, Robert A de Man, Joost P H Drenth
Source
Gastroenterology
DOI
10.1053/j.gastro.2009.07.052
PubMed
19646443
Open original source
2022Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.

Somatostatin analogs octreotide long-acting release (octLAR) and lanreotide are equally acceptable in National Comprehensive Cancer Network guidelines for neuroendocrine tumors (NETs).

Authors
Nitya Raj, Elizabeth Cruz, Sarah O'Shaughnessy, Claudia Calderon, Joanne F Chou, Marinela Capanu, Olivia Heffernan, April DeMore, Sippy Punn, Tiffany Le, Haley Hauser, Leonard Saltz
Source
JCO oncology practice
DOI
10.1200/op.22.00055
PubMed
35724357
Open original source
2002Phase 1–2 human evidence
Evidence strength B · 80/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.

Lanreotide Autogel is a new long-acting aqueous preparation of lanreotide for the treatment of acromegaly and is administered by deep sc injection from a small volume, prefilled syringe.

Authors
Ph Caron, A Beckers, D R Cullen, M I Goth, B Gutt, P Laurberg, A M Pico, M Valimaki, W Zgliczynski
Source
The Journal of clinical endocrinology and metabolism
DOI
10.1210/jcem.87.1.8153
PubMed
11788630
Open original source
2016Observational human evidence
Evidence strength B · 75/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.

Lanreotide Autogel/Depot effectively controls symptoms in patients with carcinoid syndrome associated with neuroendocrine tumours.

Authors
Philippe Ruszniewski, Juan W Valle, Catherine Lombard-Bohas, Daniel J Cuthbertson, Petros Perros, Luboš Holubec, Gianfranco Delle Fave, Denis Smith, Patricia Niccoli, Pascal Maisonobe, Philippe Atlan, Martyn E Caplin
Source
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
DOI
10.1016/j.dld.2015.12.013
PubMed
26917486
Open original source
2025Observational human evidence
Evidence strength B · 75/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Safety profile of lanreotide: a retrospective post-marketing pharmacovigilance study based on the real-world data from FAERS database.

Lanreotide, a class of synthetic somatostatin analogs (SSAs), is the recommended first-line treatment for neuroendocrine tumors (NETs) and acromegaly.

Authors
Yankun Li, Yue Han, Peng Gao
Source
Endocrine
DOI
10.1007/s12020-025-04301-z
PubMed
40468101
Open original source
2025Observational human evidence
Evidence strength B · 75/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases.

Lanreotide and Octreotide are used to treat various endocrine and neoplastic diseases.

Authors
Le Wang, Shenglin Chen, Mengying Wu, Lijuan Zhou
Source
Scientific reports
DOI
10.1038/s41598-025-03850-7
PubMed
40437077
Open original source
2010Observational human evidence
Evidence strength A · 86/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.

Long-acting somatostatin analogs (SSA) are widely used for the treatment of acromegaly achieving biochemical control of the disease in 50-75% of the patients.

Authors
Gherardo Mazziotti, Andrea Giustina
Source
Pituitary
DOI
10.1007/s11102-009-0169-z
PubMed
19189218
Open original source
2021Observational human evidence
Evidence strength B · 75/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.

The long-acting somatostatin analog lanreotide autogel is effective in the treatment of patients with neuroendocrine tumors.

Authors
Anja Rinke, Christoph Maintz, Lothar Müller, Matthias M Weber, Harald Lahner, Marianne Pavel, Wolfgang Saeger, Aude Houchard, Hanna Ungewiss, Stephan Petersenn
Source
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
DOI
10.1055/a-1342-2755
PubMed
34293802
Open original source
2017Observational human evidence
Evidence strength A · 86/100 · ProvisionalHow this is rated

This score estimates how strongly this source can support scientific claims. It is not a prestige score, and the grade does not transfer automatically to every claim that cites the source.

Grade guide: A+/A is the strongest represented support; B+/B is substantial but qualified; C is limited, indirect, observational, or preclinical; D/E is weak, mechanistic-only, anecdotal, or insufficient.

Directness
85/100
Replication
70/100

Provisional ratings are automated baselines from structured metadata. They are not completed full-text risk-of-bias reviews and may change after editorial assessment.

Methodology: WPF-ESR-1.0

The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.

Neuroendocrine tumors (NETs) are a heterogeneous group of tumors, with >50% of cases involving the gastrointestinal system or pancreas.

Authors
Michael Michael, Rocio Garcia-Carbonero, Matthias M Weber, Catherine Lombard-Bohas, Christos Toumpanakis, Rodney J Hicks
Source
The oncologist
DOI
10.1634/theoncologist.2016-0305
PubMed
28220021
Open original source

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓
Chemical identity

Molecular and structural record

Structured record
Molecular formula
C54H69N11O10S2
Molecular weight (Da)
1096.3
Amino acid sequence
[D-2-naphthylalanine]-Cys-Tyr-[D-Trp]-Lys-Val-Cys-Thr-NH2; Cys2-Cys7 disulfide
SMILES
C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O
InChI
InChI=1S/C54H69N11O10S2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74)/t30-,38-,40+,41+,42-,43+,44+,45+,46+/m1/s1
InChIKey
PUDHBTGHUJUUFI-SCTWWAJVSA-N

Chemical identity describes the recorded molecular information. It does not establish biological activity, clinical efficacy, safety, or therapeutic suitability.

Explore further

Continue through the research system

Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.

Research discovery

Compare peptides

Examine represented peptide records side by side.

Evidence system

Explore how scientific evidence is represented and reviewed.

Research hub

Enter the broader research and intelligence environment.

Methodology

Review project methods, boundaries, and interpretation rules.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

  1. 2000 · study · Temporal status not established

    Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.

    Clinical endocrinology

  2. 2002 · study · Temporal status not established

    Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.

    The Journal of clinical endocrinology and metabolism

  3. 2005 · study · Temporal status not established

    Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel.

    Metabolism: clinical and experimental

  4. 2006 · study · Temporal status not established

    Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.

    Clinical endocrinology

  5. 2009 · study · Temporal status not established

    Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months.

    Clinical pharmacokinetics

  6. 2009 · study · Temporal status not established

    Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.

    Gastroenterology

  7. 2010 · study · Temporal status not established

    Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review.

    Pituitary

  8. 2013 · study · Temporal status not established

    Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.

    Endocrine journal

  9. 2014 · study · Temporal status not established

    Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

    The New England journal of medicine

  10. 2014 · study · Temporal status not established

    Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial.

    The Journal of clinical endocrinology and metabolism

  11. 2014 · study · Temporal status not established

    Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.

    The lancet. Diabetes & endocrinology

  12. 2016 · study · Temporal status not established

    Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study.

    Pituitary

  13. 2016 · study · Temporal status not established

    EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

  14. 2016 · study · Temporal status not established

    Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.

    Endocrine-related cancer

  15. 2016 · study · Temporal status not established

    Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

  16. 2017 · study · Temporal status not established

    The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.

    The oncologist

  17. 2018 · study · Temporal status not established

    LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

  18. 2018 · study · Temporal status not established

    Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.

    JAMA

  19. 2019 · study · Temporal status not established

    Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.

    The oncologist

  20. 2019 · study · Temporal status not established

    Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.

    Gastroenterology

  21. 2020 · study · Temporal status not established

    Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN).

    BMC endocrine disorders

  22. 2021 · study · Temporal status not established

    Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association

  23. 2022 · study · Temporal status not established

    A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.

    JCO oncology practice

  24. 2025 · study · Temporal status not established

    Safety profile of lanreotide: a retrospective post-marketing pharmacovigilance study based on the real-world data from FAERS database.

    Endocrine

  25. 2025 · study · Temporal status not established

    Comparative analysis of adverse event profiles of lanreotide and octreotide in somatostatin-responsive endocrine and neoplastic diseases.

    Scientific reports

  26. 2026 · regulatory · Temporal status not established

    Regulatory review: approved

    United States (FDA — SOMATULINE DEPOT)

  27. 2026 · regulatory · Temporal status not established

    Regulatory review: approved

    United States (FDA — lanreotide acetate)

The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.

What still needs investigation

Claim traceability

No institutional claim record is currently represented for this peptide.

Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.

Researchers represented in the evidence record12 bibliographic identities · open to inspect

These are bibliographic author identities derived from represented records. Name strings are not proof of unique real-world researcher identity, and publishing organizations are not treated as institutional affiliations.

Edward M Wolin

5 represented evidence records

Years represented: 2014, 2016, 2018, 2019

Publishing organizations appearing in records: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, Endocrine-related cancer, The New England journal of medicine, The oncologist

Aaron I Vinik

3 represented evidence records

Years represented: 2016, 2018, 2019

Publishing organizations appearing in records: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, The oncologist

Alexandria T Phan

3 represented evidence records

Years represented: 2014, 2016, 2019

Publishing organizations appearing in records: Endocrine-related cancer, The New England journal of medicine, The oncologist

George A Fisher

3 represented evidence records

Years represented: 2016, 2018, 2019

Publishing organizations appearing in records: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, The oncologist

Marianne Pavel

3 represented evidence records

Years represented: 2014, 2016, 2021

Publishing organizations appearing in records: Endocrine-related cancer, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, The New England journal of medicine

Nilani Liyanage

3 represented evidence records

Years represented: 2016, 2018, 2019

Publishing organizations appearing in records: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, The oncologist

Stephan Petersenn

3 represented evidence records

Years represented: 2014, 2016, 2021

Publishing organizations appearing in records: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, Pituitary, The Journal of clinical endocrinology and metabolism

Alison Langley

2 represented evidence records

Years represented: 2014, 2016

Publishing organizations appearing in records: Endocrine-related cancer, The New England journal of medicine

Aude Houchard

2 represented evidence records

Years represented: 2016, 2021

Publishing organizations appearing in records: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, Pituitary

Beloo Mirakhur

2 represented evidence records

Years represented: 2018, 2019

Publishing organizations appearing in records: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, The oncologist

Catherine Lombard-Bohas

2 represented evidence records

Years represented: 2016, 2017

Publishing organizations appearing in records: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, The oncologist

Charles J Blijdorp

2 represented evidence records

Years represented: 2018, 2019

Publishing organizations appearing in records: Gastroenterology, JAMA

Connections

Follow the scientific relationships

Connections appear only when they are represented by the project’s underlying records.

Open 12 represented connections ↓

institution

The Journal of clinical endocrinology and metabolism

represented evidence source

institution

Pituitary

represented evidence source

institution

The oncologist

represented evidence source

institution

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

represented evidence source

institution

Clinical endocrinology

represented evidence source

institution

Gastroenterology

represented evidence source

institution

The New England journal of medicine

represented evidence source

institution

Metabolism: clinical and experimental

represented evidence source

institution

The lancet. Diabetes & endocrinology

represented evidence source

institution

Endocrine journal

represented evidence source

institution

BMC endocrine disorders

represented evidence source

institution

Clinical pharmacokinetics

represented evidence source

Traceability

Follow the record back to its source

The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.

Source publication state

A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.

Reviewer provenance state

“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.

Domain conclusion → Evidence

Connected

Evidence → Source

Connected

Source → Original record

Connected

Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.

Reconciled for 6 domain conclusions and 0 featured studies.

Detailed study-to-domain mappings and original-source paths appear in the Lanreotide evidence-governance section.

Inspect the ranked source records

Observational archive

What contributors reported

Observational archive data is intentionally separated from published scientific evidence.

Observational boundary

Insufficient eligible observations are available for display under the current filters.

Insufficient eligible observations are currently represented to display aggregated findings for this peptide.

Regulatory context

Published jurisdictional records

Regulatory status is jurisdiction-specific and time-dependent. It is presented as context, not as a recommendation for use or a substitute for scientific evidence evaluation.

Research + media

Media connected to this scientific record

Only media explicitly linked through the project’s relationship system appears here.

No scientifically connected media is currently represented for this peptide.

Sources + provenance

Read the scientific record with its boundaries intact

The public record organizes reviewed evidence; it does not establish scientific truth by itself.
Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.
Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.
Contradictory and qualifying evidence must remain visible rather than being silently discarded.
Absence of represented evidence is not evidence that research does not exist.
Research gaps identify unresolved questions; they are not negative conclusions.
Regulatory status is distinct from scientific evidence quality.
Media relationships provide context and explanation; they do not increase the strength of scientific evidence.
A section with no represented records is an incomplete project record, not a scientific conclusion.
Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.

Generated: 11/8/2026, 5:28:46 PM

global evidence atlas

Lanreotide research, ranked and separated by purpose

This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

648Discoverable source universe
500Ranked screening records
6Research domains
0Accountably approved conclusions

500 matching records · ranked 2026-09-18

Page 1 of 20

Count reconciliation: 648 discoverable source records match the peptide identity query; 500 are retained in this bounded, ranked screening view; 0 belong to the separate governed layer labeled “Accountably approved conclusions.” Domain totals overlap because one publication may inform several questions.

governance and regulatory context

Lanreotide: what this atlas does and does not establish

Last checked
2026-09-18
Accountable publication approval
Not yet approved by a named accountable reviewer. Machine screening only.

No new outcome conclusion is inferred from discovery metadata. Named accountable approval is required for governed scientific conclusions.

Regulatory status by jurisdiction

Absence of a record in this pass is not proof that no authorization exists. Status must remain jurisdiction-, product-, formulation-, and date-specific.

  • United States (FDA — SOMATULINE DEPOT)approvedchecked 2026-09-09

    SOMATULINE DEPOT is FDA-approved for long-term treatment of acromegalic patients meeting label criteria, treatment of unresectable well- or moderately differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival, and treatment of carcinoid syndrome to reduce short-acting somatostatin-analog rescue therapy.

    FDA Drugs@FDA — SOMATULINE DEPOT NDA 022074
  • United States (FDA — lanreotide acetate)approvedchecked 2026-09-09

    FDA application NDA 215395 covers a currently marketed lanreotide acetate injection product in the strengths and indications specified by its approved labeling.

    FDA Drugs@FDA — Lanreotide acetate NDA 215395

4 FDA structured product label record(s) were identified for this compound name in openFDA. Label presence reflects an approved product exists under that name; it is not a claim about the specific formulation, dose, or use being discussed anywhere else on this page.

No machine-proposed evidence-strength grades exist yet for this compound; all screening records are unassigned pending further review.

Lanreotide evidence · ranking key

How evidence is ranked

A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.

A

Practice-defining evidence

Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.

B

Strong supporting evidence

Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.

C

Contextual evidence

Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.

D

Signal-generating evidence

Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.

Tier and confidence answer different questions

Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.

Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.

peptide explorer

Structural visualization and provenance

Evidence-class labeling remains visible even when interactive rendering is unavailable. Representative geometry is not an experimentally determined or predicted biological conformation.

Fully specified molecular identity

Molecular formula
C54H69N11O10S2
Molecular weight
1096.3 g/mol
Exact identity / sequence notation
D-2-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2; Cys2–Cys7 disulfide
Identity-defining modifications
  • D-2-naphthylalanine1
  • D-Trp4
  • Cys2–Cys7 disulfide
  • C-terminal amide
PubChem CID
6918011
InChIKey
PUDHBTGHUJUUFI-SCTWWAJVSA-N

Cyclic octapeptide identity is complete; X preserves non-standard residues without inventing geometry.

Sources: NIH PubChem — Lanreotide · reviewed 2026-09-17

Representative sequence-derived model
Structure source
Generated from this record's governed amino-acid sequence
Identifier
Not applicable — not a database structure
Method
Schematic layout ordered by residue position only; not a molecular-dynamics, homology, or fold prediction
Confidence / limitations
Illustrative only. Not physically accurate; carries no structural, binding-site, or activity meaning.
Provenance
WPF governed PeptideChemistry record
Retrieved / last reviewed
2026-09-17

This is a representative, sequence-derived model ordered by residue position only. It is not the peptide's experimentally determined or predicted biological conformation, and it carries no claim about real bond angles, distances, secondary structure, binding sites, or activity.

Suggested citation

  • APA

    World Peptide Foundation. (n.d.). Lanreotide — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 20, 2026.) https://www.worldpeptidefoundation.org/directory/lanreotide

  • AMA / Vancouver

    World Peptide Foundation. Lanreotide — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 20, 2026. https://www.worldpeptidefoundation.org/directory/lanreotide